- Delpazolid
-
- $29.00 / 2mg
-
2025-12-22
- CAS:1219707-39-7
- Min. Order:
- Purity: 99.69%
- Supply Ability: 10g
- Delpazolid
-
- $1.00 / 100g
-
2019-12-23
- CAS:1219707-39-7
- Min. Order: 100g
- Purity: 98%min
- Supply Ability: G/KG/T
|
| | Delpazolid Basic information |
| Product Name: | Delpazolid | | Synonyms: | Delpazolid;Delpazolid (LCB01-0371);LCB01-0371;CS-2617;DELPAZOLID; LCB01-0371; LCB 01-0371; LCB-01-0371; LCB010371; LCB 010371; LCB-010371;(5R)-3-[4-(5,6-Dihydro-1-methyl-1,2,4-triazin-4(1H)-yl)-3-fluorophenyl]-5-(hydroxymethyl)-2-oxazolidinone;Delpazolid/(5R)-3-[4-(5,6-Dihydro-1-methyl-1,2,4-triazin-4(1H)-yl)-3-fluorophenyl]-5-(hydroxymethyl)-2-oxazolidinone;2-Oxazolidinone, 3-[4-(5,6-dihydro-1-methyl-1,2,4-triazin-4(1H)-yl)-3-fluorophenyl]-5-(hydroxymethyl)-, (5R)- | | CAS: | 1219707-39-7 | | MF: | C14H17FN4O3 | | MW: | 308.31 | | EINECS: | | | Product Categories: | | | Mol File: | 1219707-39-7.mol |  |
| | Delpazolid Chemical Properties |
| Boiling point | 481.8±55.0 °C(Predicted) | | density | 1.44±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:30.0(Max Conc. mg/mL);97.3(Max Conc. mM) | | form | A crystalline solid | | pka | 14.05±0.10(Predicted) | | color | White to off-white |
| | Delpazolid Usage And Synthesis |
| Description | Delpazolid is an oxazolidinone antibiotic. It is active against a wide range of Gram-positive bacterial clinical isolates, including resistant strains of several species, such as methicillin-resistant S. aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), and penicillin-resistant S. pneumoniae (MICs = 0.125-4 μg/ml). Delpazolid increases survival in mouse models of systemic MRSA, E. faecalis, S. pneumoniae, and H. influenzae infection (ED50s = 2.96, 4.53, 2.28, and 9.96 mg/kg, respectively). | | Uses | Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of MSSA and MRSA with a MIC90 of 2 μg/mL for both of them. | | in vivo | When administered orally, Delpazolid (LCB01-0371) shows potent protective effects against systemic infections caused by Gram-positive and Gram-negative bacteria. Against infection caused by S. aureus Giorgio (MSSA), the ED50 of Delpazolid is 4.53 mg/kg of body weight. Against S. aureus p125 (MRSA), the ED50 of Delpazolid is 2.96 mg/kg[1]. When Delpazolid (LCB-0371) is administered at 100 mg/kg daily (by gavage), the colony-forming unit (CFU) counts tend to be decreased in the lungs of mice at 7 days after infection[2]. | | IC 50 | Oxazolidinone | | References | [1] Jeong JW, et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother. 2010 Dec;54(12):5359-62. DOI:10.1128/AAC.00723-10
[2] Kim TS, et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017 Aug 24;61(9). DOI:10.1128/AAC.02752-16 |
| | Delpazolid Preparation Products And Raw materials |
| Raw materials | ethyl (3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)carbamate(WXG00214)-->2-fluoro-N-(2-(1-methylhydrazinyl)ethyl)-4-nitroaniline(WXG00212)-->3-FLUORO-4-(1-METHYL-5,6-DIHYDRO-1H-[1,2,4]TRIAZIN-4-YL)-PHENYLAMINE(WXG00213)-->1334167-59-7-->4-(2-fluoro-4-nitrophenyl)-1-methyl-1,4,5,6-tetrahydro-1,2,4-triazine-->(R)-Glycidyl butyrate-->Formaldehyde-->3,4-Difluoronitrobenzene |
|